Trajan Wealth LLC Invests $35.27 Million in IQVIA Holdings Inc. $IQV

Key Points

• Trajan Wealth LLC acquired 182,515 IQVIA shares worth approximately $35.27 million in the second quarter, making IQVIA 1.3% of its portfolio. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted earnings per share versus a $3.03 consensus estimate and $4.37 billion in revenue, up 8.7% year over year.
• The company authorized a $2 billion share buyback, while analysts maintain a “Moderate Buy” consensus with an average price target of $241.88. Several firms recently raised their targets, although insider selling and a Morgan Stanley downgrade provided counterpoints.

Trajan Wealth LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 182,515 shares of the medical research company's stock, valued at approximately $35,266,000. IQVIA comprises about 1.3% of Trajan Wealth LLC's holdings, making the stock its 21st largest position. Trajan Wealth LLC owned approximately 0.11% of IQVIA as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of IQV. Financial Freedom LLC acquired a new stake in shares of IQVIA in the 1st quarter worth $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA during the first quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in IQVIA during the fourth quarter worth about $27,000. Compass Financial Management LLC acquired a new stake in IQVIA in the second quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in IQVIA in the 4th quarter valued at approximately $27,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV stock opened at $260.30 on Tuesday. The firm has a 50 day moving average of $214.97 and a 200-day moving average of $187.62. The company has a market cap of $42.85 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $261.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Insider Transactions at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company's stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. Corporate insiders own 1.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IQV. Morgan Stanley reissued an "equal weight" rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. William Blair raised IQVIA to a "strong-buy" rating in a report on Tuesday, July 28th. Mizuho increased their price objective on IQVIA from $215.00 to $230.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Finally, Stifel Nicolaus upped their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $241.88.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source